ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting
<!-- Name:DistributionId Value:8803199 -->
<!--…
Read More...
Read More...
Browsing Tag
exebacase
ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the…
YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage…
Read More...
Read More...
ContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR…
YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage…
Read More...
Read More...
ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial…
YONKERS, N.Y., Aug. 15, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage…
Read More...
Read More...
ContraFect Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
YONKERS, N.Y., May 20, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) (ContraFect), a late…
Read More...
Read More...